scholarly journals Zepto molar miRNA-21 detection in gold Nano-islands platform toward early cancer screening

2021 ◽  
Vol 34 ◽  
pp. 100449
Author(s):  
Jalil Parchekani ◽  
Hadi Hashemzadeh ◽  
Abdollah Allahverdi ◽  
Hossein Siampour ◽  
Sara Abbasian ◽  
...  
2018 ◽  
Vol 4 (Supplement 3) ◽  
pp. 33s-33s
Author(s):  
Tochukwu Charles Orjiako

Purpose Early detection and improvements and advancements in medicine have contributed to an overall decrease in mortality and morbidity rates that result from cancer diagnoses. Despite this improvement in national and global health status, Nigerians continue to be diagnosed at a later stage and with a more aggressive disease state. This is an important observation given the impact that cancer has on the ability of individuals to function physically, psychologically, and socially within the context of their environment. It is important, therefore, to identify and target specific groups that may be less willing to present for early cancer screening. The aim of this work was to understand the characteristics of Nigerians who are likely or not to present for early cancer screening and to address the use of mechanisms by which we can ensure the timely diagnosis of preventable cancers among Nigerians. Methods Adult Nigerians (N = 144), age 18 to 71 years, presented for clinical breast examination, visual inspection with acetic acid, and prostate-specific antigen test screenings after an awareness exercise. Participants completed survey forms that included a personality inventory, early cancer detection behavior scale, and a demography profile. We used multiple regression and analysis of variance to examine predictive patterns and differences between and within groups. Results Our results indicate that income (β = .18; P < .05) is a significant determinant of early cancer detection behavior, such that higher earners were more likely to go for screening. There were also significant gender differences in current cancer detection behavior between males (mean, 0.15; standard deviation, 0.51) and females (mean, 0.47; standard deviation, 0.80). Males are less likely to engage in early detection behavior (F1,145 = 4.76; P = .03). Data also show differences between older (age > 41 years) and younger (age < 40 years) participants in the intention to screen for cancer, with older participants reporting more willingness to engage in cancer screening. Conclusion Our findings enhance our understanding of the profile of groups who are less likely to screen for cancer. Our results also suggest that awareness campaigns and free screening exercises should target these at-risk groups in Nigeria. AUTHOR’S DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc . No COIs from the author.


Cancer ◽  
1972 ◽  
Vol 30 (3) ◽  
pp. 774-781 ◽  
Author(s):  
Henry T. Lynch ◽  
William Harlan ◽  
Milton Swartz ◽  
John Marley ◽  
William Becker ◽  
...  

Gut ◽  
2013 ◽  
Vol 62 (Suppl 1) ◽  
pp. A108.1-A108
Author(s):  
J Faulkner ◽  
R Ley Greaves ◽  
J Hoare

RSC Advances ◽  
2016 ◽  
Vol 6 (95) ◽  
pp. 92267-92275 ◽  
Author(s):  
Shiya Zheng ◽  
Zixue Yang ◽  
Yanping Chen ◽  
Dan Wu ◽  
Shoubing Zhou ◽  
...  

The silica–agarose photonic beads array brings a novel approach to the combined detection of tumor markers in early cancer screening because it has high accuracy, detection reproducibility, and acceptable agreement with a common clinical method.


Cancer ◽  
1994 ◽  
Vol 74 (5) ◽  
pp. 1652-1653
Author(s):  
M. ÓN Concepci Prados ◽  
Rodolfo Alvarez-Sala ◽  
Francisco J. Garcia Rio ◽  
José Villamor ◽  
Tsuneo Kobayashi ◽  
...  

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 11545-11545
Author(s):  
Alexandre Prieur ◽  
Thibault Mazard ◽  
Eric Assenat ◽  
Marc Ychou ◽  
Sophie Gourgou ◽  
...  

11545 Background: One in two people will be diagnosed with cancer during his/her lifetime. Because we are lacking effective screening tests, most cancers are detected in late stages, when survival rates are very low. Here, we show the development of the first early cancer screening test for multiple cancers using progastrin (PG) as biomarker. The gene coding for PG is a target gene of the Wnt oncogenic pathway that is activated in almost all type of cancers, at the earliest stages of development. We showed that the neutralization of PG by a specific humanized antibody could be used for colorectal cancer treatment. Moreover, as PG is secreted by cancer cells, we can specifically detect it in the blood of persons having a cancer at early stage. Methods: Antibodies directed against PG were produced and selected for target specificity and affinity. ELISA is the most reliable assay to detect biomarker on the blood. Hence, selected antibodies were used to set up an ELISA sandwich to detect PG in the blood of patients with various types of cancers and at various stages. Results: We first set up a prototype ELISA using polyclonal antibodies. We validated our test using 223 blood samples from patients with polyps and colorectal cancers at various stages for which we observed an increased levels of PG. Then, we showed the presence of PG in the blood of 212 patients with other types of cancer, including liver, pancreatic and breast cancers, confirming that PG could be used as a biomarker for multiple types of cancers. Next, we set up our industrial ELISA using polyclonal and monoclonal antibodies called DECODE Lab and tested 245 new blood samples from patients with various types of cancer including early stages. Strikingly, using our test we were able to detect breast (AUC = 0.9638; sensitivity 70%), colorectal (AUC = 0.9635; sensitivity 73%), melanoma (AUC = 0.9882; sensitivity 87%) and cervix utery (AUC = 0.9827; sensitivity 84%) all stages combined with a high specificity of 97.5%. Finally, for early stage patients with melanoma and breast cancer, we had a sensitivity of 68% and 81% respectively. Conclusions: Taken together, the results presented here show that PG is a reliable biomarker for early cancer screening. The ELISA test that we developed is very efficient and now available for the clinic.


Sign in / Sign up

Export Citation Format

Share Document